PBS listing recommended for medical cannabis but other neurology drugs rejected by PBAC

PBS listing of cannabidiol for the treatment of Dravet Syndrome has been recommended by the Pharmaceutical Benefits Advisory Committee. At its November meeting the PBAC recommended listing of cannabidiol in combination with at least two other anti-epileptic drugs (AEDs)as a third line treatment for Dravet Syndrome The PBAC did not recommend the PBS listing of ...

Already a member?

Login to keep reading.

© 2022 the limbic